You are here
The content on this page and other TGA archive pages is provided to assist research and may contain references to activities or policies that have no current application. See the full archive disclaimer.
TGA presentation: Changes to the regulation of autologous human cells and tissue products, 7 June 2018
These presentation papers are provided on the TGA's website solely for the purpose of indicating or suggesting what TGA representatives spoke about to the various conferences and seminars to which it relates. The papers are not legislative in nature and should not be taken to be statements of any law or policy in any way.
The Australian Government Department of Health (of which the TGA is a part) advises that (a) the presentation papers should not be relied upon in any way as representing a comprehensive description of regulatory requirements, and (b) cannot guarantee, and assumes no legal liability or responsibility for, the accuracy, currency or completeness of the information contained in the presentation paper.
- Presented by: Dr Ian Prosser & Jenny Mason
- Presented at: online webinar
- Presentation date: 7 June 2018
- Presentation summary: Presentation provides an overview of the changes to the regulation of autologous HCT, including guidance on restrictions to advertising content and the need to report advert events.
Changes to the regulation of autologous cells and tissues
Dr Ian Prosser & Jenny Mason
Senior Medical Advisor
Webinar: Changes to the regulation of autologous cells and tissues, 7 June 2018
Slide 1 - Overview
- Changes to regulation of autologous cells & tissues (HCT)
- Subject to approval commence 1 July 2018
- Transition provisions
- Excluded from TGA regulation
- Exempt from certain regulatory requirements
- Regulated as a biological
- Minimal manipulation and homologous use
- Examples: Platelet-rich plasma (PrP), Stromal vascular fraction (SVF)
Slide 2 - Some regulators of products & practices
Regulation of some products & practices Products / practices Regulation Therapeutic use/ clinical trial products in humans
- Regulated by TGA
- Therapeutic Goods Act 1989
- Regulated by Food Standards Australia New Zealand
- Australia New Zealand Food Standards Code
Research (potential therapeutic) products
- Research process regulated by the National Health and Medical Research Council
- Australian Code for the Responsible Conduct in Research
- Australian Health Ethics Committee
Single patient compounded pharmaceuticals
- Regulated by Pharmacy Board of Australia
- Guidelines on the Compounding of Medicines by the Pharmacy Board of Australia
- Regulated by Australian Pesticides & Veterinary Medicines Authority
- Agricultural and Veterinary Chemicals Act 1994
Cosmetics & industrial chemicals
- Regulated under then National Industrial Chemicals Notification and Assessment Scheme
- Industrial Chemical (Notification and Assessment) Act 1989
Medical practice derived products
- Regulated by Medical Board of Australia/Australian Health Practitioner Regulatory Agency
- Health Practitioner Regulation National Law, National Registration and Accreditation Scheme
Slide 3 - Autologous human cells & tissues
- Human cell and tissue (HCT) products are those that comprise, contain or are derived from human cells and tissues.
- Autologous human cell and tissue (HCT) products are those that are removed from, and applied to, the same person, i.e. the donor and the recipient are the same.
- These include some products commonly referred to as 'stem cell treatments'.
- skin grafts for treatment of burns
- bone grafts
- bone marrow transplants
- conditioned serum
- genetically-altered lymphocytes to target cancers
- bone marrow-derived stem cells for non-haematological indications
- adipose-derived cell extracts (including stromal vascular fraction (SVF))
- blood and blood components (red cells, plasma, serum, platelets, and platelet-rich plasma (PrP))
Slide 4 - Current Therapeutic Goods (Excluded Goods) Order No. 1 of 2011 (EGO)
- Autologous cells and tissues (Medical practice)
- collected under the care of a medical practitioner, and
- manufactured for treatment of a single indication, and
- in a single course of treatment of that patient by the same medical practitioner, or by a person under their supervision
- Other autologous uses are not exempt in Australia
- Position reviewed in response to concerns
Slide 5 - Review of current Excluded Goods Order
- Concerns raised with current Order
- Advertising claims for unproven therapies
- Scope of exclusion not internationally aligned
- Scope of activity and complexity of products has changed since 2011; increasing safety concerns
- Broad public consultation on options in 2015 and 2016
- Government agreement to an option supported by the majority of stakeholders
Slide 6 - Changes to regulation of autologous cells & tissues
- Increase the level of oversight by TGA of autologous HCT
- Three levels of regulation of autologous HCT
- Excluded from TGA regulation
- Exempt from certain regulatory requirements
- Regulated as a biological
- Aligns more closely with international practice
- Some changes come in to effect from 1 July 2018; other changes will be subject to transition provisions
Slide 7 - Changes in place from 1 July 2018
Applies to all autologous HCT products:
- No direct advertising to consumers of autologous cell and tissue products from 1 July 2018 (Jenny Mason)
The following conditions also apply to Exempt and Fully Regulated products:
- Reporting of adverse events to TGA
- Compliance with all applicable standards
- Donor screening and testing (Therapeutic Goods Order 88)
Slide 8 - Transition provisions
- When autologous HCT products have been supplied before 1 July 2018
→ supply may continue until 30 June 2019
- Further transition provisions
- Exemption from GMP requirements where an application is received to seek GMP certification before 30 June 2019
- Where a full market authorisation or a CTX application is made and accepted for evaluation by 30 June 2019
- Supply can continue under the provision until a decision is made on the application
Slide 9 - Changes to regulation of autologous cells & tissues
Excluded from TGA regulation
Exclude from regulation by the TGA only those autologous cell and tissue products that are manufactured and used in an accredited hospital
- the goods were collected and manufactured by, or under the professional supervisionof, the practitioner in an accredited hospital
- For use in that patient by that practitioner or persons under their supervision
- the goods are not advertised or promoted directly to consumers;
- Designed to exclude certain autologous cells and tissues that are associated with established medical practice
- Accredited hospitals are responsible for decisions on the appropriateness of procedures and products manufactured in their institution
- For example, vascular conduits, skull flaps, cultured keratinocytes and hematopoietic progenitor cells for reconstitution of blood after chemotherapy
Slide 10 - Changes to regulation of autologous cells & tissues
Excluded from TGA regulation – Hospital accreditation
- Public and private hospitals in Australia are subject to regulation under various state, territory and national provisions
- Credentialing processes are applied by hospitals to ensure that practitioners do not work outside of their scope of practice
- Hospitals are accredited to the National Safety and Quality Health Service (NSQHS) Standards
- Hospitals should have governance and procedures in place to ensure manufacturing and use of autologous HCT is appropriate
Slide 11 - Changes to regulation of autologous cells & tissues
Excluded from TGA regulation – Manufacturing
- Collection and manufacturing must occur within the hospital and under the professional supervision of the medical practitioner
- Professional supervision requires that the medical/dental practitioner with primary responsibility for the clinical care of a patient is party to all manufacturing steps that are performed through a formal arrangement with the person or persons undertaking the manufacturing.
Specialised testing on a representative sample of the product by a third-party facility, for example sterility testing.
Offsite or third-party manufacturing of the product
Slide 12 - Changes to regulation of autologous cells & tissues
Exempt from certain regulatory requirements
Regulation under Biologicals Regulatory framework with exemptions from some requirements for autologous HCT that are:
- minimally manipulated, and
- for homologous use only, and
- manufactured and used outside a hospital by a medical or dental practitioner,
- for a patient in the same practitioner's care.
- Conditions set to limit this option to only low risk products, where there is still a high level of clinical oversight by the practitioner.
- Exempt from being on the Register (no market authorisation), and GMP
Slide 13 - Changes to regulation of autologous cells & tissues
Exempt from certain regulatory requirements – continued
- No advertising to consumers
- Single indication/single procedure
- Any treatment that involves more than a single procedure may significantly increase the risks to safety associated with traceability, sterility and quality of the product
- Treatments involving storage of the HCT do not fall within the scope of the exemption provisions.
- The primary indication for the autologous HCT product in any procedure or treatment should be clearly documented
- Guidance on what meets the definitions of minimal manipulation and homologous use
- Standards, advertising restrictions, and adverse event reporting will apply. Enforcement options will include the ability for TGA to request information and take appropriate action.
Slide 14 - Minimal manipulation
The goods have been subjected to minimal manipulation if no process or processes to which the goods have been subjected have altered any of the biological characteristics, physiological functions or structural properties of the original cells or tissues that are relevant to the purpose for which the manufacturer of the goods intends the goods to be used
- Introduces a link between the processes to which the cells and tissue are subject and the intended clinical function of the product, which is crucial for assigning an appropriate risk classification
- Removes definitional issues around the previous list of actions
- Designed to draw a line between medical practice and product manufacturing
- Not all functions may be preserved during processing, but the manufacturer must be able to show that the activity of relevant characteristics related to the intended use is sufficiently maintained. This may require a reasonable understanding of the mechanism(s) of action.
Slide 15 - Homologous use
Homologous use of the goods is use of the goods to repair, reconstruct, replace or supplement the cells or tissues of a person (the recipient), if the goods will perform the same basic function or functions in the recipient as the original cells or tissues performed in the person from whom they were collected.
- Where this definition is not met, compared with a homologous use, there would be increased safety and efficacy concerns with the use of the HCT as there is less information on which to predict the behaviour of the product.
- In determining whether the use of the HCT is homologous, the intended clinical treatment will be carefully considered, including review of the manufacturer's labelling and advertising material.
Slide 16 - Exempt from certain regulatory requirements – Example
- Preparation of platelet-rich plasma from a single uninterrupted venipuncture, for injection in to damaged tissue. Generally the processing involved does not alter the functions of the platelets so is considered minimal manipulation.
- The mechanism of platelet–rich plasma action in the treatment of musculoskeletal disorders remains to be determined and evaluation of platelet–rich plasma in clinical trials is incomplete. The basic functions that would apply to platelet-rich plasma are based on the understanding of the normal healing process of musculoskeletal tissue. The repair response of musculoskeletal tissues starts with the formation of a blood clot and degranulation of platelets. This degranulation of platelets releases a range of growth factors and cytokines into the local environment that trigger a cascade of events that lead to healing of the wound. Where it can be demonstrated or justified that the intended use of PrP can augment or stimulate healing by turning on the same repair response it could be considered to be a homologous use.
Slide 17 - Exempt from certain regulatory requirements – Example
- The intended clinical use of PrP under these exemptions still needs to be justified based on proven evidence of safety and efficacy
- PrP product would likely be considered a blood component (and regulated as a medicine), being prepared only by centrifugation, and filtration
- The exemptions only apply when the PrP is manufactured and administered by or under the supervision of a registered medical practitioner for a patient under their care and do not apply to other health practitioners
- Where equipment (such as a commercial kit) is used in the manufacture of PrP or conditioned serum it may also be subject to regulation as a medical device
- Cosmetic use of injected PrP is likely to be regulated by TGA where therapeutic claims are made or inferred. Generally, injectable products fall under the Australian legal definition for therapeutic use (for example, as they are intended to cure a defect or modify the anatomy, even if it is only for 'aesthetic' purposes).
Slide 18 - Changes to regulation of autologous cells & tissues
Regulated as a biological
Regulate under the Biologicals Regulatory Framework those autologous human cell and tissue products that are:
- manufactured and used outside an accredited hospital, and
- more than minimally manipulated, or
- for non-homologous use.
- Products may still be accessed through clinical trials or compassionate use schemes
- Market authorisation and GMP requirements apply.
Slide 19 - Regulated as a biological - Example
Adipose tissue example:
- A manufacturer processes adipose tissue (enzymatic or physical dissociation) with the aim to dissociate cell-cell contacts and isolate the cellular portion. The resultant product (such as stromal vascular fraction (SVF)) is injected back in to patients for reputed anti-inflammatory uses. In this case the cells responsible for the intended use and to which the determination of minimal manipulation applies (e.g. mesenchymal stem cells) would be considered the autologous HCT product. Such methods used to disrupt adipose tissue would be considered beyond minimal manipulation. The process applied to isolate the cells is likely to result in changes to their properties, e.g. activation state or surface molecule expression, which could significantly impact the cells characteristics or functions.
Slide 20 - Regulated as a biological - Example
- Adipose tissue may be collected and then reinjected with minimal manipulation, or may be subjected to processing to extract the cellular portion from the tissue.
- The HCT extracted from adipose includes various cellular fractions (of varying purity), and are collectively referred to as Stromal Vascular Fraction (SVF).
- Homologous uses include:
- providing cushioning and support for other tissues, including the skin and internal organs
- storing energy in the form of lipids, and
- insulating the body.
- Where the HCT provided to the recipient is a cell extract, the determination of homologous use would make reference to the basic functions of the cells located in the adipose, rather than those of the tissue collectively.
- SVF isolated from adipose tissue is used to treat musculoskeletal conditions, such as arthritis or tendonitis by regenerating or promoting the regeneration of articular cartilage or tendon. This application is considered a non-homologous use.
Slide 21 - Implementation
- Staged implementation – advertising restriction, transition
- In the first instance, we seek to inform, educate and assist stakeholders
- Communication strategy over next 12 months to target different stakeholder groups, including consumer groups
- Teleconferences and face-to-face meeting options
- Submitted questions after the Advertising presentation
- Primary contact for further enquiries is firstname.lastname@example.org
- Link to current guidance: Biologicals regulatory framework proposed changes to start on 1 July 2018
Slide 22 - Advertising Unapproved HCT Therapies
- Unapproved autologous HCT products which are regulated as exempt biologicals from 1 July 2018 will be prohibited from being advertised to consumers under the Therapeutic Goods Act 1989 (the Act).
- Likewise, autologous HCT products which are proposed to be excluded from the operation of the Act from 1 July 2018 may not be advertised to consumers.
Slide 23 - Making claims to arrange supply of unapproved HCT therapies
- Making claims to arrange supply of unapproved HCT therapies (as distinct from advertising) is also prohibited under the Act unless :
- Those goods are subject to an exemption, approval or authority under one of a number of different schemes included in the Act.
- The claim is limited to the terms of that exemption/ approval; and
- communicated between the relevant parties to that exemption, approval or authority
- This means that claims to arrange supply of unapproved HCT therapies cannot be broadly made to consumers or health professionals.
Slide 24 - Education / guidance
- New "Advertising hub" planned for website
- Easier to locate from homepage
- Access to education, guidance, complaint form, inquiry form etc
- Three e-learning modules under development
- Australian Regulatory Guidelines on Advertising Therapeutic Goods
- Consumer-specific materials:
- Fact sheets – lodging complaints, identifying non-compliant ads
- Short video on advertising requirements
*Large file warning: Attempting to open large files over the Internet within the browser window may cause problems. It is strongly recommended you download this document to your own computer and open from there.